Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively

The treatment of hyperprolactinemia is based on the use of dopamine agonists, mainly bromocriptine (BRC) and cabergoline (CAB). They reduce tumour size effectively and restore gonadal function. However, there is a difference in drug sensitivity between CAB and BRC in patients with prolactinoma, alth...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Chao, Sun, Ruixin, Wen, Guodao, Zhong, Chunyu, Yang, Jin, Zhu, Junhao, Cong, Zixiang, Luo, Xiaoying, Ma, Chiyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472389/
https://www.ncbi.nlm.nih.gov/pubmed/31000722
http://dx.doi.org/10.1038/s41419-019-1526-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472389/
https://www.ncbi.nlm.nih.gov/pubmed/31000722
http://dx.doi.org/10.1038/s41419-019-1526-0

Ejemplares similares